Healio Innovations in DME: Leveraging Clinical Biomarkers and Durable Therapies
The integration into practice of sustained delivery devices and therapies that offer longer duration of action have further revolutionized the management of patients with diabetic macular edema (DME). However, selecting patients who will optimally benefit from these newer therapies can be challenging. Biomarkers of vascular instability are emerging, which could help guide treatment decisions and provide useful tools for monitoring disease control. This CE activity utilizes Curbside Consults, a dynamic and interactive case-based platform that will highlight these therapeutic strategies for the management of DME that reduce dosing frequency and enhance anatomic outcomes. Experts in the field also review the role of novel biomarkers to guide early clinical decision-making and evaluate treatment options for patients with DME based on the latest clinical evidence.
Cost: Free
View Offer chevron_rightKey Features
Innovations in DME: Leveraging Clinical Biomarkers and Durable Therapies
0.75 AMA PRA Category 1 Credit(s)
Topics Covered
DR/DME
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the role of novel biomarkers that can be used to guide early clinical decision-making for enhanced visual outcomes for patients with DME.
- Outline the latest evidence regarding the impact of dual-targeted options on blood vessel stability and macular leakage.
- Select treatment for patients with DME based on the latest clinical evidence.
Target Audience
The intended audience for this activity is retina specialists involved in the management of patients with DME.
Additional credit info
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 15, 2025, to December 14, 2026.